MK-7684A-005
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors
Completed
Trial purpose
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected advanced solid tumors. The primary hypothesis is that pembrolizumab/vibostolimab co-formulation is superior to pembrolizumab alone in terms of objective response rate or progression-free survival in participants with cervical cancer.
View full trial information on Clinicaltrials.govNATIONAL TRIAL REFERENCE NUMBER
NCT05007106
When you talk with your doctor or clinical trial team member, please have the national trial reference number available.
Eligibility
Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.
Conditions
Cholangiocarcinoma, Endometrial Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Hepatocellular Carcinoma, Ovarian Neoplasms, Squamous Cell Carcinoma Of Head And Neck, Stomach Neoplasms, Triple Negative Breast Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms
Age Range
18+
Sex
Male/Female
Current trial Phase
Phase 2
Tests the medicine or vaccine in approximately 100 to 500 participants. In the case of medicines, participants usually have the disease or condition the investigational medicine is designed to treat. In vaccine trials, the participants are usually healthy. Phase 2 trials may happen in a doctor’s office, a clinic, or a hospital.
Trial start and end dates
- Trial start date 09-16-2021
- Estimated primary completion date 08-05-2025
- Estimated trial completion date 08-05-2025
Trial Locations
Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.
Sorry, there are no locations found.